Isembyld (Apitegromab)

Apitegromab is a medicine for people with spinal muscular atrophy (SMA) who already take another SMA medicine. It is given as an infusion into a vein. It works by blocking a natural signal that holds back muscle growth, to help muscles get stronger.

Brand names:Isembyld
Medication

What people taking Isembyld (Apitegromab) report

Every report comes from a Lived member, sent anonymously.

Have you tried Isembyld (Apitegromab) for SMA (Spinal Muscular Atrophy)?

NameHow it went

About Isembyld (Apitegromab)

What It's For

Apitegromab, sold as Isembyld, is a prescription treatment for spinal muscular atrophy (SMA), a genetic disease in which the nerve cells that control movement gradually die, leaving muscles weak and wasted. It was approved in the US in 2026 for adults and children aged 2 and older. It is an add-on, not a replacement. Apitegromab is approved only for people who are already taking an SMN2-targeted treatment (survival motor neuron 2, a backup gene these medicines act on), such as nusinersen (Spinraza) or risdiplam (Evrysdi). Those medicines help the body make more of the survival motor neuron (SMN) protein that motor nerves need, which slows or stops the loss of nerve cells. They often leave lasting weakness, though, and apitegromab is meant to work on the muscle side of the problem.

How It Works

Muscles naturally produce myostatin, a protein that acts as a brake on muscle growth. Myostatin is made in an inactive form and has to be switched on before it can signal to muscle cells. Apitegromab is a monoclonal antibody, a lab-made immune protein designed to attach to one specific target. It binds to the inactive forms of myostatin and stops them from being switched on, which releases some of that brake. The aim is to help muscles that still receive nerve signals become stronger and work better. It does not repair the SMA gene or the nerve cells themselves, which is why it is used alongside a medicine that does.

Dosage & Administration

Apitegromab is given as an infusion into a vein (IV) once every 4 weeks, usually at an infusion center or clinic. The dose is based on body weight, and each infusion takes about 1 to 2 hours. A higher dose was tested in the main trial but did not work better, so it is not recommended. If an infusion is missed, it can be given as soon as possible, with the next one scheduled 4 weeks later. Alternatively, the missed dose can be skipped and treatment resumed on the original schedule. The care team can help decide which fits better. The usual SMA medicine continues as before.

Side Effects

In the main trial, the effects reported more often with apitegromab than with placebo included colds and other upper respiratory infections, vomiting, cough, other viral infections, headache, stomach bugs, sore throat and skin reactions such as rash or hives. Diarrhea, pain or bruising where the infusion goes in, joint pain and tiredness were also more common. Broken bones occurred in about 9 percent of people on the approved dose compared with about 2 percent on placebo, and some happened without a clear fall. New pain, swelling or tenderness over a bone, a limb that looks out of place, or new reluctance to move an arm or leg should be checked by the care team right away. Pneumonia and serious breathing problems during chest infections were also seen in a small number of people. A blood test for a muscle enzyme called CPK (creatine phosphokinase) often rose during treatment, usually without causing symptoms.

Interactions & Warnings

The main warning is a higher chance of fractures, including serious thigh bone fractures. People with SMA already tend to have thin bones, and most fractures in the studies occurred in people with low bone density, earlier fractures or contractures (tight, shortened muscles and joints). The care team will weigh this before starting and will reconsider whether to continue if a fracture happens. There is not enough information to know whether apitegromab is safe during pregnancy or breastfeeding. Antibodies like it can cross the placenta, and animal studies showed effects on offspring development and later fertility. Anyone who is pregnant, planning a pregnancy or breastfeeding should discuss this with the prescriber. No specific drug interactions are listed on the label, but the full medication list should still be shared.

What to Expect

The goal is a gain in motor function, or at least less decline, rather than a dramatic change. In the main trial, nonambulatory children aged 2 to 12 on nusinersen or risdiplam were scored on a 66-point scale of motor abilities such as sitting unassisted and standing. After a year, scores rose about 1 point on apitegromab and fell about 1 point on placebo. About a third of children on apitegromab improved by 3 points or more, compared with about one in seven on placebo. Evidence is thinner outside that group. Teens and young adults showed a similar trend, and use in adults relies partly on modeling rather than direct trial results. People who walk, adults over 65 and those treated only with gene therapy were not studied. Treatment involves monthly infusions, regular motor assessments and attention to bone health, with the care team reviewing over time whether the benefit is worth continuing.

Questions to Ask Your Doctor

  1. 1.What realistic change in strength or daily function should we look for, and how will we measure it?
  2. 2.Given my bone density and fracture history, how high is my fracture risk, and what can we do to lower it?
  3. 3.Does apitegromab fit my current SMA treatment, including if I have had gene therapy?
  4. 4.Where will the infusions happen, and how will insurance coverage work?
  5. 5.How long should we try it before deciding whether it is helping enough to continue?

Last reviewed • Oct 2026

Educational content, not medical advice.